MedTrace Logo

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

NCT07098338 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 278

Last updated 2026-04-29

No results posted yet for this study

Summary

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.

Conditions

Interventions

DRUG

Rilvegostomig

Rilvegostomig will be administered as IV infusion.

DRUG

Ramucirumab

Ramucirumab will be administered as IV infusion.

DRUG

Dato-DXd

Dato-DXd will be administered as IV infusion.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-07
Primary Completion
2029-04-06
Completion
2029-04-06
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • China
  • Japan
  • Singapore
  • South Korea
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07098338 on ClinicalTrials.gov